Horizons in the Pharmacotherapy of Obesity

Arch, Jonathan R.S. (2015) Horizons in the Pharmacotherapy of Obesity. Current Obesity Reports.

Horizons in pharmacotherapy final submitted for online.pdf

Download (417kB) | Preview


Obesity drugs have had a chequered history. In the recent past, only the low efficacy, pancreatic lipase inhibitor orlistat was available worldwide and it was little used. The 5HT2C agonist lorcaserin, and two combinations of old drugs have been approved in the United States but not in Europe. The diabetes drug liraglutide has been approved in both the US and Europe and seems likely to be most widely accepted. In view of regulators’ caution in approving obesity drugs, some (like beloranib) may initially be progressed for niche obesity markets. New drug targets have been identified in brown adipose tissue with the aim of not only activating thermogenesis but also increasing the capacity for thermogenesis in this tissue. Attempts are being made to match the efficacy of bariatric surgery by mimicking multiple gut hormones. Unapproved pharmacotherapies are tempting for some patients. Others remain optimistic about more conventional routes to pharmacotherapy.

Item Type: Article
Uncontrolled Keywords: Obesity pharmacotherapy; obesity drugs; liraglutide; niche obesity markets; obesity drug targets; unapproved obesity pharmacotherapy
Subjects: R Medicine > RM Therapeutics. Pharmacology
Depositing User: Jon Arch
Date Deposited: 04 Sep 2015 14:14
Last Modified: 15 Feb 2018 13:52
URI: http://bear.buckingham.ac.uk/id/eprint/86

Actions (login required)

View Item View Item